All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What results are needed prior to therapy initiation in newly diagnosed AML?

During a meeting of the AML Hub Steering Committee on June 1, 2022, Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, chaired a discussion session on the topic “What results are needed prior to therapy initiation in newly diagnosed AML?”, previously identified as an unmet educational need within AML treatment.

Bullinger begins by inviting discussion on the importance of a patient’s history, with Brian Huntly and Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, highlighting particular relevance in cases where chromosomal abnormalities may not indicate a patient’s risk level, or in the context of myelodysplastic syndromes (MDS). The discussion moves on to explore factors that impact the choice of treatment, including patient eligibility, test turnaround times, cytogenetic profiles, and the importance of patient empowerment. Andrew Wei outlines practical recommendations such as routine collection of RNA before treatment initiation, and invites the committee to comment on approaches to complex or monosomal cytogenetics in higher-risk patients.

Finally, the committee discusses the need for measurable residual disease (MRD) testing prior to initiation of therapy, highlighting recent data and the impact on transplantation, and comparing different treatment approaches and the role of posttransplant maintenance.

What results are needed prior to therapy initiation in newly diagnosed AML?